← All trials
NCT05665647
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 29, 2022
- Primary completion
- Jan 26, 2023
- Completion date
- Feb 14, 2023
- First posted
- Dec 27, 2022
- Last posted
- Feb 21, 2023
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Simcere Pharmaceutical Co., LtdLead sponsor
- Shandong first medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.